Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
By H. Friedman, M. Prados, P. Wen, T. Mikkelsen, D. Schiff, L. Abrey, W. Yung, N. Paleologos, M. Nicholas, R. Jensen and 4 more. Journal of Clinical Oncology, 2009
2,472 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/e28bd499ddbabb44d3c2be7b1749cf750c340310
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010, background): “enhancement as early as 1 to 2 days after initiation of therapy and commonly result in high radiologic response rates of 25% to 60%.(43-46)”
- The microenvironmental landscape of brain tumors (2017, background): “…Cancer Cell 31, March 13, 2017 suggest that these strategies may be optimally used in the recurrent setting in combination with additional therapies (Friedman et al., 2009; Kreisl et al., 2009), rather than as frontline monotherapy on newly diagnosed, untreated disease (Gilbert et al., 2014).”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “High response rates and a steroid-sparing effect have been observed with the administration of bevacizumab (± irinotecan); however, the effect is frequently short-lived and may be due exclusively to changes in vascular permeability; the effect on life expectancy remains unknown [III, C] [56, 57].”
- Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “Bevacizumab was associated with a radiological response (the so-called pseudo-response) in 30-40 % of the cases in single arm studies associated with irinotecan [73, 74].”
- Antibody therapy of cancer (2012, methodology): “For example, tumour response rate was used for the approval of bevacizumab in glioblastoma and for gemtuzumab ozogamicin in relapsed acute myeloid leukaemia (AML), and progression-free survival was used for the approval of panitumumab in colorectal cance”
- Current Challenges and Opportunities in Treating Glioblastoma (2018, background): “In a Phase II study that led to conditional FDA approval, the longest median progression-free survival (5.6 months) was seen with a combination of bevacizumab and irinotecan (Friedman et al., 2009), while longest overall survival (12 months) resulted from lomustine + bevacizumab (Taal et al., 2014).”
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Consequently, in February 2004, the FDA approved the use of bevacizumab for the Bevacizumab monotherapy was also efficacious in recurrent glioblastoma multiforme (GBM), with response rates in 20% to 25% of patients 85,86 , resulting in FDA approval in 2009.”
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020, result): “Toxic effects were consistent with the known safety profiles of nivolumab and bevacizumab.(10,11)No new safety signals were observed, including no apparent increase in the incidence of neurological TRAEs.”